Ocorrência dos cânceres de mama e endometrial em mulheres em terapia de reposição hormonal na menopausa: uma revisão de literatura / Occurrence of breast and endometrial cancers in women on hormone replacement therapy in menopause: a literature review

Gustavo Mariano Rodrigues Santos, Igor Antônio Galvão Vieira, Beatriz Costa, Maria Eduarda Boni Kist, Fernanda Alves Luz, Lara Telles Moura, Matheus Jannuzzi Moreira de Mendonça

Abstract


INTRODUÇÃO: O uso da Terapia de Reposição Hormonal (THR) é prescrito para tratamento de alguns sintomas decorrentes da menopausa. O uso indiscriminado dessa terapêutica parece elevar os riscos de determinadas neoplasias. METODOLOGIA: Trata-se de uma revisão integrativa de literatura, com busca na base de dados Pubmed. Utilizou-se os descritores "Estrogen Replacement Therapy", "Hormone Replacement Therapy", “Menopause”, "Breast Neoplasms", "Breast Cancer", "Endometrial Neoplasms", "Endometrial Cancer", associados aos operadores booleanos AND e OR. Incluíram-se publicações entre 2016 e 2021 nos idiomas português, inglês e espanhol. RESULTADOS: Foram selecionados 20 artigos publicados em periódicos internacionais, sendo 17 estudos de Coorte, dois de Caso-Controle e um Ensaio Clínico Randomizado duplo-cego. DISCUSSÃO:  Os estudos analisados sugerem boa resposta no controle dos sintomas pós menopausa pela TRH. Porém, apresenta associação com risco de desenvolvimento de neoplasias de mama e endométrio, ao passo que o uso de estrogênio isolado demonstrou pouca associação. Quando comparados em relação a raça, mulheres brancas apresentam maior risco em relação a negras e asiáticas. CONCLUSÃO: Houve associação do uso de TRH com desenvolvimento das neoplasias estudadas. A duração da terapia, o tipo de hormônio, o momento de início, a via de administração e a população submetida ao tratamento, parecem impactar neste desfecho.

 

 


Keywords


Terapia de Reposição Hormonal, Câncer de mama, Fatores de risco, Câncer de endométrio.

Full Text:

PDF

References


Takahashi TA, Johnson KM. Menopause. Med Clin North Am. 2015;99(3):521-34.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C., Stefanick ML,et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.

Palacios S, Stevenson JC, Schaudig K, Lukasiewicz M, Graziottin A. Hormone therapy for first-line management of menopausal symptoms: Practical recommendations. Womens Health (Lond). 2019;15:1745506519864009.

Pickar JH, Archer DF, Kagan R, Pinkerton JV, Taylor HS. Safety and benefit considerations for menopausal hormone therapy. Expert Opin Drug Saf. 2017;16(8):941-954.

Falk RT, Manson JE, Barnabei VM, Anderson GL, Brinton LA, Rohan TE, Cauley JA, Chen C, Coburn SB, Pfeiffer RM, Reding KW, Sarto GE, Wentzensen N, Chlebowski RT, Xu X, Trabert B. Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone? Int J Cancer. 2019 Feb 15;144(4):730-740.

Cagnacci A, Venier M. The Controversial History of Hormone Replacement Therapy. Medicina (Kaunas) 2019; 55(9): 602.

Cobin RH, Goodman NF; AACE. Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause - 2017 update. Endocr Pract. 2017;23(7):869-880.

Holm M, Olsen A, Au Yeung SL, Overvad K, Lidegaard Ø, Kroman N, et al. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort. BJOG. 2019;126(1):55-63.

Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat. 2016;155(2):365-73.

Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394:1159–68.

Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol. 2017;33(2):87-92.

Gaudet MM, Barrdahl M, Lindström S, Travis RC, Auer PL, Buring JE, et al. Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. Breast Cancer Res Treat. 2016;155(3):531-40.

Dartois L, Fagherazzi G, Baglietto L, Boutron-Ruault MC, Delaloge S, Mesrine S, et al. Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort. Int J Cancer. 2016;138(10):2415-27.

Pines A. No increased death toll for long-term menopausal hormone therapy. Climacteric. 2017;20(6):531-532.

Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, Hoti F, Vattulainen P, Gissler M, et al. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. Menopause. 2016;23(11):1199-1203.

Román M, Graff-Iversen S, Weiderpass E, Vangen S, Sakshaug S, Hofvind S, et al. Postmenopausal Hormone Therapy and Breast Cancer Prognostic Characteristics: A Linkage between Nationwide Registries. Cancer Epidemiol Biomarkers Prev. 2016;25(11):1464-1473;

Simin J, Tamimi R, Lagergren J, Adami HO, Brusselaers N. Menopausal hormone therapy and cancer risk: An overestimated risk? Eur J Cancer. 2017;84:60-68.

Brusselaers N, Tamimi RM, Konings P, Rosner B, Adami HO, Lagergren J. Different menopausal hormone regimens and risk of breast cancer. Ann Oncol. 2018;29(8):1771-1776.

Ettinger B, Quesenberry C, Schroeder DA, Friedman G. Long-term postmenopausal estrogen therapy may be associated with increased risk of breast cancer: a cohort study. Menopause. 2018;25(11):1191-1194.

Jones ME, Schoemaker MJ, Wright L, McFadden E, Griffin J, Thomas D, et al. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?. Br J Cancer. 2016;115(5):607-615.

Zhang Y, Ruan X, Willibald M, Seeger H, Fehm T, Neubauer H, et al. May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer? Gynecol Endocrinol. 2016;32(1):58-60.

Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Zeng D, et al. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. J Natl Cancer Inst. 2017;109(9):djx001.

Yoo TK, Han KD, Kim D, Ahn J, Park WC, Chae BJ. Hormone Replacement Therapy, Breast Cancer Risk Factors, and Breast Cancer Risk: A Nationwide Population-Based Cohort. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1341-1347.

Liu L, Zhang J, Wu AH, Pike MC, Deapen D. Invasive breast cancer incidence trends by detailed race/ethnicity and age. Int J Cancer. 2012 Jan 15;130(2):395-404.

Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018;25(1):11-20.

Chlebowski RT, Barrington W, Aragaki AK, Manson JE, Sarto G, OʼSullivan MJ, et al. Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial. Menopause. 2017;24(2):133-141.

DeBono NL, Robinson WR, Lund JL, Tse CK, Moorman PG, Olshan AF, et al. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt). 2018;27(3):377-386.

Heikkinen S, Koskenvuo M, Malila N, Sarkeala T, Pukkala E, Pitkäniemi J. Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment. Cancer Causes Control. 2016;27(2):249-58.




DOI: https://doi.org/10.34117/bjdv7n7-114

Refbacks

  • There are currently no refbacks.